Acquisition of Hema Diagnostics Systems, LLC (Tables)

6 Months Ended

Jan. 31, 2018

Business Combinations [Abstract]

Net purchase price of HDS

	Stock Price at Closing		Shares		Fair Value
Purchase price:
Common Stock at closing	$	4.77		53,191	$	253,721
Common Stock after closing	$	4.77		20		95
Common Stock post reverse stock split	$	4.77		230,000		1,097,100
Total purchase price					$	1,350,916

Fair Value Assumptions Used in Accounting for Warrants

	January 31, 2018			July 31, 2017
Exercise price		2.50			2.50
Time to expiration		3.96 years			4.47 years
Risk-free interest rate		2.29	%		1.84	%
Estimated volatility		120.67	%		122.7	%
Dividend		—			—
Stock price at valuation date	$	3.75			5.05

Fair Value Assumptions Used in Accounting for Call Options

	January 31, 2018			July 31, 2017
Risk-free interest rate		2.14	%		1.34	%
Estimated volatility		154.5	%		143.9	%
Remaining Term		1.96			2.47
Stock price at valuation date	$	3.75			5.05

Carrying amount of goodwill and other intangible assets

	Other Intangibles, net		Goodwill		Total
Balance as of July 31, 2017	$	2,911,377	$	—	$	2,911,377
Current period amortization		—		—		—
Additions from pharmacy acquisition		276,380				276,380
Balance as of January 31, 2018	$	3,187,757	$	—	$	3,187,757